U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C16H16FN3O2S
Molecular Weight 332.381
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 1
Charge 0

SHOW SMILES / InChI
Structure of BF-227 C-11

SMILES

CN([11CH3])C1=NC=C(S1)\C=C\C2=NC3=CC=C(OCCF)C=C3O2

InChI

InChIKey=GSZMUPHKOPBPPS-BOSKHGQCSA-N
InChI=1S/C16H16FN3O2S/c1-20(2)16-18-10-12(23-16)4-6-15-19-13-5-3-11(21-8-7-17)9-14(13)22-15/h3-6,9-10H,7-8H2,1-2H3/b6-4+/i1-1

HIDE SMILES / InChI

Molecular Formula C16H16FN3O2S
Molecular Weight 332.381
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 1
Optical Activity NONE

Approval Year

Substance Class Chemical
Created
by admin
on Sat Dec 16 12:04:38 GMT 2023
Edited
by admin
on Sat Dec 16 12:04:38 GMT 2023
Record UNII
CI7PP08FLN
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
BF-227 C-11
Code English
5-(2-(6-(2-FLUOROETHOXY)-2-BENZOXAZOLYL)ETHENYL)-N-METHYL-N-(METHYL-11C)-2-THIAZOLAMINE
Systematic Name English
(11C)BF-227
Code English
(11C)-BF 227
Code English
2-THIAZOLAMINE, 5-(2-(6-(2-FLUOROETHOXY)-2-BENZOXAZOLYL)ETHENYL)-N-METHYL-N-(METHYL-11C)-
Systematic Name English
Code System Code Type Description
PUBCHEM
16040297
Created by admin on Sat Dec 16 12:04:38 GMT 2023 , Edited by admin on Sat Dec 16 12:04:38 GMT 2023
PRIMARY
FDA UNII
CI7PP08FLN
Created by admin on Sat Dec 16 12:04:38 GMT 2023 , Edited by admin on Sat Dec 16 12:04:38 GMT 2023
PRIMARY
CAS
947602-44-0
Created by admin on Sat Dec 16 12:04:38 GMT 2023 , Edited by admin on Sat Dec 16 12:04:38 GMT 2023
PRIMARY
Related Record Type Details
TARGET->RADIOLIGAND
Results: GSS patient showed obvious retention of (11C)BF-227 in the cerebellum, and lateral and medial temporal cortices. The three GSS patients showed significantly higher SUVRp in the lateral temporal cortex, thalamus, and cerebellum (Figure) when compared to aged normal controls. Furthermore, when compared to the AD group, the GSS group showed significant elevation of SUVRp in the medial temporal cortex, thalamus, and cerebellum. Although 2 GSS patients showed retention of BF-227 in most brain regions, the youngest GSS patient showed BF-227 retention only in the cerebellum, thalamus, and medial temporal cortex, but not in the neocortex. Furthermore, 2 sporadic CJD patients showed no obvious BF-227 retention in any of the brain regions examined).
Related Record Type Details
ACTIVE MOIETY
Results: Dementia with Lewy bodies (DLB) and Alzheimers disease (AD) patients exhibited an abnormal (11C)BF-227 retention in the neocortex compared with healthy control subjects. In DLB patients, (11C)BF-227 retention in the lateral temporal and posterior cingulate cortices was significantly higher than that in healthy controls. In addition, DLB patients showed significantly higher (11C)BF-227 uptake in the amygdala than healthy controls and AD patients.